Why the study?
What is the safety profile of fluoxetine compared to TCAs and placebo in patients with major depressive disorder?
What is the safety profile of fluoxetine compared to TCAs and placebo in patients with major depressive disorder?
This review pools safety data from over 4,000 patients in clinical trials to update the safety profile of fluoxetine.
Answers are grounded in this paper and cite their sources.
May refine fluoxetine safety considerations in MDD; leaves open prospective validation against TCAs and placebo.
Fluoxetine is a new antidepressant agent which is a selective inhibitor of neuronal serotonin uptake; it has minimal affinity for muscarinic, dopaminergic, histaminic, serotonergic, or noradrenergic receptors (Stark et al , 1985). This specificity of activity suggests that fluoxetine may have a side-effect profile which is different from previously available antidepressants. The safety of fluoxetine has been extensively studied: several hundred patients have received the drug continuously for more than one year - some have had therapy for 5 years or more. Previous reviews of the safety of fluoxetine (Wernicke, 1985; Zerbe, 1986) have described a smaller population of patients than is now available. This review is drawn from data pooled from comparative clinical trials, which included 4336 patients: fluoxetine - 2938, tricyclic antidepressants (TCAs) - 599, and placebo - 799 patients. The TCAs studied were amitriptyline, imipramine, and doxepin. Most patients were adults with major depressive disorder, and the most common study design was a 6-week comparative double-blind phase, followed by unblinded long-term treatment. While the core of this study is a data base of 2938 fluoxetine-treated patients, all serious adverse events reported in over 7500 fluoxetine-treated patients worldwide, as of mid-1987, have been included.
No takes yet. Share an insight, caveat, or question.
Glenn L. Cooper (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: